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Invasive treatment of claudication is indicated for
patients unable to adequately ambulate during
cardiac rehabilitation
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Background: Cardiac rehabilitation (CR) is of proven benefit for patients with coronary artery disease. Patients who
successfully complete CR have a statistically significant reduction in the risk of fatal myocardial infarction (MI) and
all-cause mortality. Peripheral arterial disease (PAD) is common in patients with coronary artery disease.
Objectives:We investigated whether PAD prevents the successful completion of CR and cardiac risk reduction andwhether
invasive treatment of claudicant patients who cannot walk sufficiently to successfully complete CR is indicated.
Methods: The records of 230 consecutive CR patients were reviewed for attendance, target heart rate, and Walking
Impairment Questionnaire (WIQ) values to compare PAD among successes and failures. Failure of CR was defined as
inability to walk sufficiently to achieve target heart rate. Markov decision analysis using published data for endovascular
and open intervention for claudication was used to compare outcomes of treatment strategies in which PAD is untreated
(current standard), PAD is treated only if it interfered with CR, and treatment of PAD in all patients before initiating CR.
Results: Of 230 patients, 126 had complete records for analysis. Ankle-brachial indices (ABIs) were documented for 39
patients. Overall, 40% of patients failed CR. Failure was significantly more common in patients with claudication (76%)
than in those without (26%; odds ratio [OR], 8.9; 95% confidence interval [CI], 3.7-21.7; P < .001). The presence of
PAD, determined by the WIQ walking distance score, was significantly higher in the failure group (34%) vs the success
group (17%; OR, 2.5; 95% CI, 1.1-6.0; P  .03). The presence of PAD, determined by ABI, was higher in the failure
group (39%) vs the success group (14%; OR, 3.8; 95% CI, 0.8-17.9; P .08). Logistic regression analysis when CR failure
was adjusted for age and gender was significantly associated with presence of PAD based on WIQ walking distance score
(OR, 2.8; 95% CI 1.1-7.1; P .03). A strategy of invasive therapy only if PAD interfered with the successful completion
of CR would save an additional 54 lives per 10,000 patients compared with no intervention.
Conclusions: PAD is a significant cause of CR failure, preventing patients from successfully completing the program and
achieving a reduction in risk of fatal cardiac events. Invasive treatment of PAD in patients who fail CR is indicated, with
an expected lifesaving outcome. (J Vasc Surg 2009;49:1217-25.)Heart disease remains the major cause of death in the
United States. Despite recent declines in mortality, cardio-
vascular disease claimed 652,091 lives in 2005, with
530,926 deaths in those aged 65 years.1 Many more
patients experienced disabling or nonfatal myocardial in-
farctions (MIs). Numerous strategies, both pharmacologic
and invasive, have been developed to reduce the enormous
toll of this disease.
One of the most effective but least utilized strategies is
cardiac rehabilitation (CR).2,3 The benefits of CR have
been unequivocally established. The subject of numerous
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doi:10.1016/j.jvs.2008.11.066randomized, controlled studies and meta-analyses, CR has
been shown to reduce cardiac mortality by 31%, all-cause
mortality by 27%, and improve cardiac function, blood
pressure, left ventricular function, and quality of life in
patients with symptomatic ischemic and valvular heart dis-
ease.4-8 These benefits are related to increases in functional
capacity and reductions in myocardial oxygen requirements
that develop by daily exercising to a nearly maximal heart
rate. Walking at a sufficiently brisk pace to drive heart rate
to this level also conditions the leg muscles so that less
strenuous walking after CR produces a slower heart rate
and lower systolic blood pressure, reducing cardiac strain
and the risk of fatal MI.9
Although comprehensive CR is a multifaceted program
involving pharmacotherapy and counseling as well as exer-
cise, treadmill walking may be the most important for a
reduction in fatal cardiac events.10,11 A sufficient intensity
of treadmill exercise is necessary to improve cardiac and
peripheral muscle conditioning and endurance. Training
intensity is determined by establishing a target heart rate,
which is 55% to 90% of the maximum heart rate recorded
during pre-rehabilitation stress test.12 The patient strives to
reach the target heart rate during each exercise session. As
conditioning and endurance increase, the exercise expendi-
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patient to continuously improve his or her physical status
without risking excessive cardiac demands. Increasing
walking distance is a strong predictor of a reduction in
cardiac risk.13 Therefore, for maximal reduction in cardiac
risk, patients must be able to walk sufficiently to regularly
achieve their target heart rate. Those who cannot exercise
to this extent maintain their high risk for a fatal cardiac
event.
The need for aggressive cardiovascular care of the pa-
tient with intermittent claudication (IC) has also been well
established. It is now recognized that IC is a marker for
advanced systemic atherosclerosis and a significantly higher
risk of fatal cardiac events. Cardiac deaths account for
60% of the deaths in these patients, and as many as 16% to
25% will die of a fatal MI 5 years of onset of symp-
toms.14-16 It can be estimated from large epidemiologic
studies that claudicant patients have a threefold to sixfold
higher risk of a fatal cardiovascular event than those with
similar risk factors but without symptomatic lower extrem-
ity ischemia.17 Therefore, patients with IC and known
ischemic or valvular heart disease would benefit signifi-
cantly from CR.
Unfortunately, the exercise demands of CRmay exceed
the capabilities of claudicant patients. Current recommen-
dations specify that treadmill exercise therapy should begin
at a speed of 1.6 to 4.0 km/h at 0% grade for 20 minutes.18
The upper end of this initial rate approximates that of
treadmill exercise testing at 3.5 km/h performed in the
vascular laboratory to elicit symptoms of claudication in 5
minutes.19 Patients with IC may not be able to walk with
sufficient intensity to reach their target heart rate.
The primary purpose of this study was to determine
whether peripheral arterial disease (PAD) or IC interferes
with the successful completion of CR and the resultant risk
reduction of fatal cardiac events. The secondary purpose
was to evaluate through Markov decision analysis whether
the invasive treatment of patients with IC who cannot walk
sufficiently to successfully complete CR is indicated to
reduce total fatal cardiac events.
METHODS
The Advocate Lutheran General Hospital Health Care
Institutional Review Board approved the protocol, and all
patients gave written informed consent before they were
included in the study.
Study population. To determine whether IC inter-
feres with the successful completion of CR, the records of
all patients who began a supervised CR program at Advo-
cate Lutheran General Hospital from January 2004 to
December 2004 were reviewed. Demographic informa-
tion, type of cardiac impairment, program attendance, and
target heart rate performance were noted.
Patient enrollment in the CR program was at the
request of the patient’s cardiologist based on that physi-
cian’s judgment of the patient’s need, perceived benefit,
and exercise ability. By hospital standard, only those pa-
tients who were deemed by their medical team to becapable of participation in a treadmill-based exercise pro-
gramwere referred. Patients withmild tomoderate ICwere
included. Excluded from enrollment were those with evi-
dence of severe claudication and inability to safely walk on
a treadmill and those with critical limb ischemia. Both men
and women were eligible for participation, and there were
no age restrictions.
Evaluation of PAD. The presence and degree of PAD
and IC were assessed by the Walking Impairment Ques-
tionnaire (WIQ) and, in a subset of patients, calculation of
the ankle-brachial index (ABI). The WIQ was obtained by
self-administration or by telephone interview after patients
had completed the supervised CR program or had with-
drawn. Raw data for calf or buttock pain on ambulation,
walking distance, walking speed, and stair climbing were
converted to summary scores for analysis as described by
Regensteiner et al.20 The threshold value of the summary
scores that defined PAD in the study population was deter-
mined with weighted mean cutoff values from the litera-
ture.21 Because CR is directed toward improvement in
cardiac conditioning through endurance, it was assumed
that walking distance, rather than walking speed or stair
climbing, would be the most important correlate of the
impact of PAD on this exercise program.
All patients participating in the study were invited to
undergo determination of ABI and 31% responded. The
ABI was measured with a hand-held Doppler probe and a
random-zero sphygmomanometer. For each leg, the ABI
was calculated as the highest systolic blood pressure in the
ankle from the right or left posterior tibial or dorsalis pedis
arteries divided by the highest brachial systolic pressure.
The leg with the lowest ABI was used in the analyses. The
presence of PAD was defined as an ABI of 0.90.22
To confirm that this subset of responders was represen-
tative of the larger group and did not represent selection
bias, the mean age, gender, smoking history, presence of
diabetes, and obesity in this subset were compared with the
entire study population (Table I).
CR program. CR was a multifaceted program of 12
weeks of monitored exercise training comprising 36 ses-
sions (3 sessions per week) in addition to other pharmaco-
logic and counseling therapies. For physical conditioning,
patients were asked to do different muscle exercises, which
Table I. Patient characteristics of total group vs
ankle-brachial index group
Characteristic Totala ABI subseta
Patients, No. 126 39
Age, years 65.7 66.7
Male gender, No. (%) 93 (73.8) 26 (66.7)
Diabetes, No. (%) 24 (19.0) 10 (25.6)
Obesity,b No. (%) 43 (34.1) 16 (41.0)
Tobacco,c No. (%) 58 (46) 21 (53.8)
aP  .05 for all comparisons.
bActive or historic use.
cDefined as a body mass index 30 kg/m2.included 10minutes of warm-up, 20minutes of exercise on
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rowing, or weight training), and 10 minutes of cool-down.
Before patients began the program, their target heart rate
was calculated to determine the goal of exercise therapy. The
heart rate reserve method of Karvonen was used which requires
measurement of resting heart rate (HRrest) while standing and
measurementof peakheart rate (HRmax) duringgradedexercise.
Target heart rate (THR) was calculated according to the Kar-
vonen equation: THR  (HRmax –HRrest)  0.7  HRrest,
where0.7 represents the70% level of peak activity recommended
by the American Heart Association.23 Improvement in cardiac
function occurs because as the patient becomes more physically
fit, the amount of exercise performed before reaching the target
heart rate increases. This is monitored during each rehabilitation
session. Successful completion ofCRwas defined as the comple-
tionofat least32sessionsandtheachievementof targetheart rate
during one of the last three sessions. All patients receiving
-blockers began taking the drug before the pre-CR cardiac
stress test andcontinued taking thedrug throughoutCR.There-
fore, the target heart range identified was appropriate and was
used to assess successful completion of CR.
We assumed that IC might interfere with the successful
completion of CR, either by causing the patient to prema-
turely discontinue participation because of calf discomfort
while walking or by limiting the patient’s walking effort,
which would manifest as a failure to reach target heart rate.
Therefore, for the purposes of this study, CR failure was
defined as the completion of 32 of the 36 prescribed
exercise sessions or an inability to reach target heart rate
during the performance of supervised exercises within the
36-week timeframe.
Model structure. A Markov decision model was de-
veloped to compare fatal events of three treatment strate-
gies, base, selective, and comprehensive, for patients requiring
CR.24,25 The primary cohort for analyses (the base-case)
consisted of 64-year-old men who entered a supervised CR
program. The intended goal was to determine whether the
invasive treatment of claudicant patients who could suc-
cessfully complete CR would result in an overall reduction
in total fatal events.
The base strategy models current practice trends. Pa-
tients are referred for supervised CR. Those patients unable
to adequately ambulate to meet therapeutic targets un-
dergo no further treatment other than medical therapy.
They therefore retain a higher risk of fatal cardiac events
compared with those who successfully complete the pro-
gram. This represents the current treatment of patients
with IC requiring CR.
In the selective strategy, patients participating in a su-
pervised CR who are unable to walk sufficiently well to
meet the exercise demands of the program undergo subse-
quent evaluation for IC by ABI measurement. Those with
evidence of IC by history and ABI are further evaluated
with subtraction angiography or magnetic resonance an-
giography (assumed proportion is 1:1). If PAD is docu-
mented, the lesion is treated with percutaneous translumi-
nal angioplasty (PTA) or bypass grafting, depending on the
severity and level of disease. Suprainguinal PTA with stentplacement, aortoiliac grafting, infrainguinal PTA, and fem-
oropopliteal bypass were included as revascularization pro-
cedures. During or after revascularization, some patients
have complications or procedural failures and are unable to
continue CR, whereas most patients continue with their
CR program.
The comprehensive strategy involves the screening, di-
agnosis, and treatment of IC for every patient before the
initiation of a supervised CR program. The same approach
to patient evaluation and intervention as in the selective
strategy is applied.
For the purpose of the study, CR failure was defined as
a discontinuation of the treadmill exercise program, com-
pleting 32 sessions or the inability to reach target heart
rate. In follow-up, patients may experience a fatal or non-
fatal cardiac event (ie, defined as acute angina or nonfatal
MI) or die from noncardiac causes.
For each of the three strategies, the model kept track of
time spent in one of the following health states: (1) pre-
rehabilitation, (2) successful rehabilitation, (3) failed reha-
bilitation, (4) nonfatal cardiac event, (5) cardiac death or
noncardiac death. A Markov cycle tree was updated every 6
months, after which patients’ clinical status was estimated
to model lifetime health benefits. Long-term life expect-
ancy was calculated on the basis of age- and sex-specific
mortality rates from standardUnited States life tables of the
general population.26
Data sources. Treatment effectiveness data for the
model were retrieved from the literature and from primary
data collection. Table II summarizes estimates from the
best available evidence of the included variables, with prob-
ability distributions representing the uncertainty around
the estimates and the source of the data.3,10,27-50 Because
the literature lacks data on the frequency of PAD as a cause
of CR failure, the original patient data collected from the
Advocate Lutheran General Hospital Cardiac Rehabilita-
tion Center was used.
Effectiveness. For development of the Markov deci-
sion tree, the proportion of patients who failed CR due to
PAD was based on the ABI measured in the subset of our
patient sample. Strategies that have included revasculariza-
tion for PAD assumed that revascularization was possible in
95% and was beneficial for improving walking ability in 90%
of these treated patients.31,43,44 For the Markov model,
then, successful completion of CR for selective and com-
prehensive treatment strategies included not only the per-
centage of patients defined in the base strategy but also 85%
(95% technical success  90% effectiveness) of those with
PAD who were treated and returned to complete the
exercise program. Hazard rates for fatal cardiac events
during follow-up for patients with and without CR were
calculated from probabilities derived from representative
studies (ie, those who compared CR with lifestyle changes
only), which were included in a systematic review by Taylor
et al (Table II).10
To explore the effect of uncertainty in the parameter
estimates, extensive one-way, two-way, and multi-way sen-
sitivity analysis were performed.
after
own t
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with the t test. The 2 test was used to assess the statistical
significance of differences of dichotomous variables of gen-
der, smoking, diabetes mellitus, and obesity between the
CR failure group and success group. The 2 test was also
used to compare the proportion of patients with PADbased
on the walking distance score, the speed score, and ABI
Table II. Data included in the Markov model on rehabilit
Variable
Probabilities for CR
Successful current CR
Successful CR after treatment PAD
Failure CR due to symptomatic PAD
Symptomatic PAD among CR patients
12-month rates of cardiac events during follow-up
Fatal cardiac event after CR
Fatal cardiac event without CR
Probabilities for PAD status
Suprainguinal disease conditional on the presence of PAD
Suitable for angioplasty
Suprainguinal lesion
Infrainguinal lesion
Lesion is suitable for surgerya
Occlusive vs stenotic
Aortoiliac lesion
Fem-pop
Vein available for bypass vs PTFE
Mortality rate for PAD procedures and imaging
Iliac PTA with selective stent placement
Femoral or popliteal PTA
Aortic bifurcation grafts
Infrainguinal bypass
Diagnostic imaging (angiography and MRI)
Probability of systemic complications of PAD proceduresb
Iliac PTA with selective stent placement
Femoral or popliteal PTA
Aortic bifurcation grafts
Fem-pop or infra-pop bypass
6-month patency in PAD patients
Iliac PTA with selective stent placementc
Stenosis
Occlusion
Femoral or popliteal PTA without stent
Stenosis
Occlusion
Femoral or popliteal PTA with stent
Stenosis
Occlusion
Aortic bifurcation grafts
Fem-pop or infra-pop bypass
Above knee anastomosis
Autologous vein
PTFE
Below knee anastomosis
Autologous vein
PTFE
ALGH, Advocate Lutheran General Hospital; CR, cardiac rehabilitation
percutaneous transluminal angioplasty; PTFE, polytetrafluoroethylene.
aIn the Markov model, we assumed that 5% of the lesions were not suitable
bSystemic complication is defined as all events that occurred within 30 days
cPatency estimates for iliac PTA with selective stent placement have been shmeasurements between the CR failure group and the CRsuccess group. Two-tailed values of P  .05 were consid-
ered statistically significant for all analyses.
In addition, age and sex are risk factors for PAD and
may also be associated with CR failure.51 Therefore, logis-
tic regression models to adjust for age and sex were used to
examine the association between CR failure and the pres-
ence of PAD, based on the WIQ walking distance and
strategies for patients with coronary artery disease
Base case
value Range
Literature or
database source
0.56 0.10-0.90 ALGH
0.71 0.10-0.90 See text
0.18 0.05-0.75 ALGH
0.26 0.05-0.75 ALGH; 3, 27
0.03 0.01-0.05 10
0.05 0.01-0.07 10
0.56 0.12-0.85 28
0.51 0.43-0.59 28, 29
0.18 0-0.25 28, 29
0.95 0-0.99 See text
0.2 0-0.50 30
0.36 0-0.60 31
0.2 0-0.50 ALGH
0.005 0-0.01 32-34
0.005 0-0.01 35, 36
0.02 0-0.04 37, 38
0.026 0-0.04 39
0.00033 0.0003-0.002 40, 41
0.007 0-0.01 34
0.003 0-0.01 35, 42
0.02 0.01-0.04 38
0.085 0.03-0.13 43
0.95 0.70-0.99 44
0.8 0.70-0.99 44
1 0.98-1.00 45
0.88 0.81-0.94 45
1 0.99-1.00 45
0.99 0.92-1.00 45
0.98 0.98-0.99 46
0.95 0.90-0.99 47, 48
0.87 0.84-0.90 49, 50
0.94 0.93-0.95 49
0.7 0.65-0.75 49, 50
I, magnetic resonance imaging; PAD, peripheral arterial disease; PTA,
rgery.
the procedure and that required additional medical care.
o equal those for iliac PTA with primary stent placement.ation
; MR
for suspeed scores. Logistic regression analysis based on the ABI
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presence of PAD was not performed because the sample
with ABI measurements was too small. To evaluate
whether the presence of PAD indicated by the WIQ corre-
sponded to the presence of PAD as indicated by the ABI,
the 2 test and Pearson correlations coefficients were used.
These analyses were performed in SPSS 11.0.1 software
(SPSS, Chicago, Ill).
RESULTS
IC and CR failure. The records of 230 consecutive
patients undergoing CR were reviewed. Of these 230 pa-
tients, 126 had also completed a WIQ and defined the
study population. Table III summarizes the patient charac-
teristics and severity of cardiac disease. The mean patient
age was 65  11 years (range 31-91 years), and 93 (74%)
were men (Table III). Before CR, 63 of 126 patients (50%)
had sustained a MI, 58 (46%) had angina, 3 (2%) had an
aortic valve replacement, 1 (1%) had a mitral valve repair,
and 1 (1%) was assigned to CR for congestive heart failure.
Treatment before CR included PTCA in 53 patients (42%),
CABG in 49 (39%), and both treatments in seven (6%).
The prevalence of PAD among patients undergoing
CR depended on the parameter used for detection but was
high overall, even in this group of patients in which those
with severe claudication or critical limb ischemia were
excluded. PAD was present according to the WIQ claudi-
cation symptoms data in 29%, by theWIQwalking distance
score in 24%; and by the ABI in 26%.
Based on the definitions of success and failure, 75 of
Table III. Patient characteristics: Success vs failure
Characteristic Total
Successful
CRa
Failed
CRa
Patients, No. (%) 126 (100) 75 (60) 51 (40)
Male gender, No. (%) 93 (74) 58 (77) 35 (69)
Age, mean  SD, y 65  11 66.9 64.3
Diabetes, No. (%) 24 (19) 12 (16) 12 (24)
Obesity,b No. (%) 43 (34) 23 (31) 20 (39)
Tobacco,c No. (%) 58 (46) 36 (48) 22 (43)
-Blockade, No. (%) 111 (88) 66 (88) 45 (88)
Principle diagnosis
Angina, No. (%) 58 (46) 38 (51) 20 (39)
MI, No. (%) 63 (50) 35 (47) 28 (55)
CHF, No. (%) 1 (1) 0 (0) 1 (2)
Valve disease, No. (%) 4 (3) 2 (3) 2 (4)
Principle procedure
PTCA, No. (%) 53 (42) 31 (41) 22 (43)
CABG, No. (%) 49 (39) 31 (41) 18 (35)
PTCA/CABG, No. (%) 7 (6) 5 (7) 2 (4)
Valve repair, No. (%) 4 (3) 2 (3) 2 (4)
None, No. (%) 13 (10) 6 (8) 7 (14)
CABG, Coronary artery bypass grafting; CHF, congestive heart failure; CR,
cardiac rehabilitation; MI, myocardial infarction; PTCA, percutaneous
transluminal coronary angioplasty; SD, standard deviation.
aP  .05 for all comparisons.
bBody mass index 30 kg/m2.
cActive or historical use.126 patients (60%) successfully completed CR and 51(40%) failed. Patient demographics presented in Table III
were not statistically different between the CR success and
failure groups (P  .05 for all).
The presence of IC, as determined by WIQ data, was
significantly higher in the failure group. Of the 126 patients
in the cohort, 37 reported calf or buttock pain on ambula-
tion and 28 (76%) failed CR. The remaining 89 patients
reported no calf or buttock pain, and only 23 (26%) failed
rehabilitation (calf or buttock pain vs no pain, odds ratio
[OR], 8.9; 95% confidence interval [CI], 3.7-21.7; P 
.001)
To determine whether other types of pain were also
significantly associated with CR failure, patients who re-
ported only joint pain without claudication symptoms were
also examined. No statistical significance was noted be-
tween the 23 patients who reported only joint pain or
stiffness, in which nine (39%) failed, compared with the
remaining group of 103 without joint pain, of whom 42
failed (41%; joint pain vs no joint pain, P .89). There was
a significant difference between the rate of failure of those
with claudication compared with those with joint pain only
(IC vs joint pain, OR, 4.8; 95% CI, 1.57-14.9; P  .004).
Based on the WIQ walking distance score, PAD was
present in 17 of 51 patients (34%) in the CR failure group
but in only 13 of 75 patients (17%) in the CR success group
(OR, 2.5; 95% CI, 1.1-6.0; P  .03). When ABI measure-
ment was used as the PAD discriminant, seven of 18
patients (39%) in the CR failure group and three of 21
patients (14%) in the CR success group had PAD (OR, 3.8;
95% CI. 0.8-17.9; P  .08). Logistic regression analysis
documented that CR failure, adjusted for age and sex, was
significantly associated with the presence of PAD based on
theWIQwalking distance score (OR, 2.8; 95%CI, 1.1-7.1;
P  .03).
Markov analysis of treatment strategies. In a hypo-
thetical cohort of 10,000 patients, the selective strategy, in
which ABI measurement is performed for patients who fail
CR, followed by a diagnostic workup and revascularization
for IC if needed, yielded a lower number of fatal events
compared with the base and comprehensive strategies. Al-
though the selective strategy included more fatal peripro-
cedural events due to the revascularization procedures, the
reduction in the number of fatal cardiac events outweighed
the total number of fatal procedurally related events, saving
an additional 54 lives compared with the base strategy
(Table IV).
Sensitivity analysis revealed that the selective strategy
remained the best treatment option if the probability of
fatal periprocedural events was8%. If this probability was
8%, the base strategy was preferred. In addition, the base
strategy was preferred if the difference in the annual rate of
a fatal cardiac event between the CR success group and CR
failure group was0.008. The comprehensive strategy was
never preferred because of the additional deaths and com-
plications incurred by treating all those with IC, including
some who would be able to successfully complete the
exercise training.
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Cardiac rehabilitation is an effective method for reduc-
ing the risk of fatal cardiac events. By consistently walking
to reach a target heart rate, determined generally as 70% of
the maximum heart rate noted on the pretreatment stress
test, the patient can safely improvemyocardial conditioning
and endurance without risking excessive cardiac strain dur-
ing exercise. This conditioning is manifested as an increase
in walking distance before reaching target heart rate and,
subsequently, a lower risk of fatal MI. Kavanagh et al52
monitored for a median of 9 years (range, 4-26 years) 6956
men who underwent a 12-month cardiac exercise program
after MI (4713 patients) or coronary artery bypass grafting
(2243 patients).52 They compared walking distance with
peak oxygen uptake for predicting subsequent death. The
investigators noted that an increase in walking distance was
of significantly greater value in assessing prognosis after MI
or coronary artery bypass grafting. An increase in walking
distance of 1.3 to 2.8 miles resulted in a 24% reduction in
death, and an increase in ambulatory ability of 2.8 miles
yielded a 48% reduction in death.
Unfortunately, the hallmark of IC is a significant reduc-
tion in walking distance and speed. To our knowledge, this
is the first study to examine the effect of IC on the success-
ful completion of CR and to evaluate the potential lifesav-
ing benefit of the invasive treatment of IC to permit the
successful completion of CR and a reduction in risk of
cardiac mortality.
The WIQ was selected as the primary survey tool to
determine the presence of PAD and IC in the patients
undergoing CR because of its excellent correlation with the
degree of ambulatory impairment.53 The WIQ permitted
the identification of pain syndromes during ambulation as
well as limitations on walking distance. Because walking
distance is more important than walking speed for the
improvement in cardiac conditioning, this was used as the
major parameter of PAD and IC.
The WIQ data on the patients undergoing CR indicate
that the prevalence of PAD is high, even though those with
Table IV. Intermediate outcomes: Number of fatal cardia
complications from PAD revascularization procedure in th
Per 10,000 patients
Strategy 1, Patient No.
CR
Strategy 2, Patient No.
ABI if CR fails, followed by diagnostic work-up and
revascularization for PAD if needed
Strategy 3, Patient No.
ABI in all patients before CR and diagnostic work-up and
revascularization for PAD if needed
ABI, Ankle-brachial index; CR, cardiac rehabilitation; PAD, peripheral arte
aUnrelated to PAD revascularization.
bCardiac event is defined as acute angina or myocardial infarction.severe claudication symptoms or with signs or symptoms ofcritical limb ischemia were excluded from participation.
This is not unexpected, given that atherosclerosis is a
systemic process and a significant correlation exists between
a reduced ABI and coronary artery disease.
Those with PAD and IC have a significantly higher
failure rate than those without lower extremity ischemia.
Correlations of independent variables of calf or buttock
pain with ambulation, joint pain, walking distance, and ABI
with CR attendance and attainment of target heart rate
demonstrate that individuals with IC harbor a significant
disadvantage for the successful completion of CR and a
reduction in mortality risk. The presence of joint pain had
no significant effect on the successful completion of the
exercise program.
More than 75% of those reporting symptoms of IC
failed CR and approximately one-third of patients who
failed CR have symptoms of claudication or PAD. This
finding is not surprising nor does it conflict with published
reports on the success of supervised vascular exercise pro-
grams. Vascular exercise programs use claudication pain as
the end point for exercise. Walking a short distance to the
point of claudication may gradually enhance calf muscle
function but will unlikely lead to cardiac strengthening and
a reduction in cardiac death. Those patients with short-
distance claudication may be unable to walk far or fast
enough to reach the target heart rate that would be estab-
lished as the end point of exercise in CR. Improvement in
cardiac conditioning requires that the heart rate be consis-
tently pushed into the target heart rate range. Thus, pa-
tients with symptoms of IC are unlikely to benefit from
referral to a CR program without additional treatment.
To determine whether the invasive treatment of IC to
permit the successful completion of CR is indicated, a
Markov decision model was constructed. The model was
populated with data obtained in the literature for percuta-
neous and open treatment of IC. Because there are no
published data on the prevalence of IC among those un-
dergoing, succeeding, or failing CR, the data from the
Advocate Lutheran General Hospital Cardiac Rehabilita-
ntsa during follow-up and number of fatal periprocedural
e-case analysis in a hypothetic cohort of 10,000 patients
al cardiac
tb during
llow-up
Fatal periprocedural
complications from PAD
revascularization procedure
Total fatal
events during
follow-up
1838 0 1838
1742 42 1784
1826 64 1890
sease.c eve
e bas
Fat
even
fo
rial dition registry was used. Although data from a single center
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been configured according to the standards set by the
American Association of Cardiovascular and Pulmonary
Rehabilitation and the American Heart Association. The
demographics of the study group population are similar to
that reported in other studies on CR.
The base cohort of patients established for the Markov
model was appropriate given the characteristics of the ac-
tual patients as listed in Table III. The base strategy repre-
sents the current treatment of patients enrolled in CR.
Those who fail to complete the exercise program are simply
managed with medical therapy and maintain their high risk
of cardiac death. No further attempt is made to systemati-
cally evaluate and treat the underlying cause of failure. The
base treatment program was compared with two strategies
directed toward the invasive treatment of IC to determine
whether the risks and mortality of IC treatment and subse-
quent CR would be lower than that of the base strategy.
Compared with the base strategy, the selective strategy
would result in 54 fewer deaths per 10,000 patients. In this
strategy, only those who failed CR because of IC would be
treated; those with IC capable of reaching target heart rate
would not be treated. An estimated 85% of those who
underwent invasive treatment for claudication would re-
cover sufficiently to return and successfully complete CR.
Although no reported data are available to confirm this
assumption, it is consistent with the degree of improvement
experienced in those who have been treated for IC.54,55
This strategy would yield the highest rate of successful
completion of CR with the lowest associated mortality.
In the comprehensive strategy, all patients with PAD or
symptoms of IC would be treated before the initiation of
CR. Because the data derived from patient record review
indicated that some patients with PAD or symptoms of IC
could successfully complete CR without treatment, more
patients would undergo revascularization than would be
necessary. The deaths associated with this broad treatment
strategy would offset the gains achieved through the suc-
cessful completion of CR.
The study has several limitations. Data were derived
from a single-center review to document the effect of IC as
a cause of CR failure. Although inclusion criteria for referral
at this center were standardized and reflected the recom-
mendations of the American Heart Association, exclusion
criteria were not. Patients who were judged by their pri-
mary care physician or cardiologist to be unable to perform
treadmill walking were generally excluded. This clearly
introduced bias into the data set. However, because pa-
tients with evidence of significant walking impairment were
excluded from participation in CR, it is likely that the true
impact of PAD and IC is actually significantly greater than
reflected in the results of this study.
Determining the specific cause of CR failure due to
early termination or failure to reach target heart rate has
been challenging for investigators. Multiple reasons have
been identified, including distance from the center, cost of
participation, work, and other obligations. Also, patients
referred for CR may have additional comorbidities andinfirmities such as chronic obstructive pulmonary disease or
arthritis. Because of this, identifying the single, major cause
of early termination or failure to reach target heart rate for
an individual is difficult. Even direct informal discussion
with some of this study’s participants failed to conclusively
implicate claudication as the only cause for failure. There-
fore, several different indicators of PAD and IC were used
to determine the effect of lower extremity arterial occlusive
disease on CR. Because arthritis is also a common cause for
difficult or limited ambulation in older patients, joint pain
was also correlated with CR failure, but no adverse effect on
successful completion was noted. These multiple indepen-
dent correlations strongly implicate IC as a cause of CR
failure despite the lack of a standard tool or test to confirm
a specific cause.
Markov decision analysis was used to assess the poten-
tial benefit of invasive treatment of PAD and IC to reduce
the risk of fatal events by increasing the likelihood of CR
success and reducing the risk of cardiac and all-cause mor-
tality. As in every decision model, this is a simulation of
reality and based on data included in the model. In sensi-
tivity analysis, however, the uncertainty of these data was
evaluated and the results were found to be robust.
CONCLUSIONS
The ability of vascular surgeons to effectively treat PAD
and IC with both percutaneous and open techniques has
been recognized for decades. The rationale for doing so has
not. The benefits of initiating treatment based on the
traditional indications of intervention for lifestyle-limiting
or job-threatening claudication have not been well substan-
tiated with regard to long-term patient benefit. This has led
to the polarization of vascular specialists, with some liber-
alizing intervention to treat all patients with claudication,
whereas others refrain from invasive therapy because of
concerns of unjustifiable risk to life and limb for no defined
benefit. The data reported here suggest a clear indication
for invasive intervention in the subgroup of patients with
IC, known ischemic heart disease, and the inability to
successfully complete CR. Despite the small risks of inter-
vention, treatment is warranted for the reduction in fatal
cardiac events conferred by CR and an improvement in
cardiac conditioning.
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Dr Karl Illig (Rochester, NY). I am a big fan of this concept,
and congratulate you on pursuing this. Maybe everyone else in the
room is ahead of me, but I only became aware of this issue a few
years ago when patients started showing up unable to pursue
aggressive cardiac rehabilitation because they couldn’t walk. Your
analysis is great, but it is fairly mathematical. I now consider
inability to complete cardiac rehabilitation a pretty good indication
for aggressive revascularization. Do you share this bias?
Dr John V. White. I agree with you. I think that this is an
excellent indication for invasive intervention in the claudicant. We
needed to establish a database, which is why we undertook the
mathematical analysis. We are carefully following these patients
and we will report our clinical results in the future.
DrAnil Hingorani (Brooklyn, NY). I’d like to actually reflect
on those comments. I think we have a very active cardiac rehab
program andwe have had the same type of issues where patients are
not able to complete their cardiac rehab program because of their
claudication. I am concerned, though, in your Markov model you
only resulted in 41 lives per 10,000 patients who would benefit
from this? The number seems somewhat small in terms of you have
to do 10,000 patients to get 41 patients to benefit.
DrWhite.We were looking strictly at mortality. Our hypoth-
esis stated that if you cannot reduce patient mortality through
cardiac rehab and you did nothing, those patients remain at high
risk. So the initial passthrough of the Markov model, which is
indeed quite complex, was simply to look at overall mortality. As
we began to work with the model, looking at quality-adjusted
life-years, for example, there is a statistically significant benefit in
the selective treatment of claudicants. The comprehensive strategy
where all claudicants would be identified prior to entry into a
program, and treated, probably will never reach a statistical signif-
icance no matter how we vary the probability parameters.
DrHingorani.Andwhat was the cost per quality life per year?
Dr White. It is about $70,000.
Dr John Blebea (Philadelphia, Pa). It appears to me that you
are presenting an association and not necessarily a causal relation-
ship. Do these patients fail cardiac rehab because specifically of
limiting claudication, or was the ABI [ankle-brachial index] and
claudication simply a surrogate marker of more advanced disease?
You are also proposing a very aggressive interventional policy on
the assumption that mortality will subsequently be decreased.
However, if lower extremity occlusive disease is but a marker of
more severe systemic atherosclerotic disease, will doing a bypass inDr White. Those are two great questions, John. The answer
appears to be that if we allow these patients to successfully com-
plete their cardiac rehabilitation, then there will be a reduction in
mortality, at least as predicted by all the meta-analyses available on
cardiac rehabilitation.
As to your first question, there are a plethora of articles trying
to ascertain why patients don’t return for cardiac rehabilitation.
Claudication as sole cause has never been evaluated. Although ABI
and WIQ [Walking Impairment Questionnaire] scores do seem to
be indirect measures, a direct survey of patients yields no greater
information. Therefore, because the walking impairment question-
naire has such great statistical correlation with walking distance and
other outcomes, we used that as our major parameter for ascertain-
ing the presence of peripheral arterial disease and symptoms of
intermittent claudication.
Dr Marc Mitchell (Jackson, Miss). I enjoyed your presenta-
tion and have a comment. This situation is not just limited to
patients with cardiac disease. We now have a handful of patients
that underwent joint replacement surgery and were unable to
rehabilitate because of vascular disease. Once we treated their
peripheral arterial disease, they were able to go on with their
orthopedic rehabilitation. This problem is probably more wide-
spread than we really think.
Dr White. Thank you for those comments and I completely
agree.
DrGeorge Andros (Van Nuys, Calif). As surgeons, we think of
interventions in terms of endovascular and open; but a supervised
walking program is an intervention as well. What you are asking these
people to do is to walk for their hearts instead of their legs. It has been
well documented that supervised walking programs ameliorate clau-
dication symptoms as well as increase walking distance and ABIs. If
patients don’t experience cardiac symptoms before the vascular clau-
dication symptoms occur during exercise, what is the harm in having
the patient undertake a peripheral arterial walking programfirst? If the
legs don’t improve enough, both subjectively andobjectively, to allow
sufficient cardiac exercise with its accrued benefits then you can always
proceed with leg revascularization. Bear in mind, however, as the
Oxford University group showed many years ago, endoluminal ther-
apy may not be as durable in achieving sustained improvements in
claudication as a walking program. You might be back where you
started.
Dr White. That is a very insightful observation. We did look
at, for the purposes of the Markov model, a combined cardiac and
vascular rehabilitation program, which clearly dominates all other
strategies.
